You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

programmed cell death

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC, Solid Tumors, Programmed Cell Death-1 (PD1, PD-1) Trial (MK-2870, Pembrolizumab, Carboplatin)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • +4 more
  • MK-2870
  • +2 more
  • (no location specified)
Sep 15, 2023

NSCLC Trial in Wuhan (Cadonilimab, Pemetrexed, Carboplatin)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Wuhan, Hubei, China
    Qian Chu
Aug 18, 2023

NSCLC (NSCLC) Trial in Shanghai (Tumor treating fields(EFE-P100), Docetaxel injection)

Not yet recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • Tumor treating fields（EFE-P100）
  • Docetaxel injection
  • Shanghai, China
    Shanghai Pulmonary Hospital
Dec 21, 2022

Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell

Recruiting
  • Primary Immune Deficiency
    • Bethesda, Maryland
    • +6 more
    Feb 2, 2023

    Esophageal Squamous Cell Carcinoma Trial (Paclitaxel, Irinotecan, Pembrolizumab)

    Recruiting
    • Esophageal Squamous Cell Carcinoma
    • Chuo-ku, Tokyo, Japan
      National Cancer Center Hospital ( Site 3700)
    Jan 31, 2023

    PD1/PDL1 Inhibitors Treatment Duration in Patients With NSCLC

    Recruiting
    • Non-small Cell Lung Cancer
    • Monza, Italy
      ASST-Monza Ospedale San Gerardo
    Jun 9, 2022

    Tumor-Infiltrating Lymphocytes and Programmed Cell Death -

    Recruiting
    • Breast Cancer
    • +2 more
    • Observational Study
    • Lucknow, Uttar Pradesh, India
      Sanjay Gandhi Postgraduate Institute of Medical Sciences
    Feb 11, 2022

    Non Small Cell Lung Cancer, Immune Checkpoint Inhibitor, EGFR Exon 21 Mutation Trial in Peking (Pembrolizumab, pemetrexed,

    Not yet recruiting
    • Non Small Cell Lung Cancer
    • +2 more
    • Peking, China
      Peking Union Medical College Hospital
    Nov 16, 2023

    Hepatocellular Carcinoma Non-resectable, Transarterial Chemoembolization, Tyrosine Kinase Inhibitor Trial in Chengdu (lenvatinib

    Enrolling by invitation
    • Hepatocellular Carcinoma Non-resectable
    • +3 more
    • lenvatinib + sindilimab/carrelizumab
    • TACE
    • Chengdu, Sichuan, China
      West China Hospital of Sichuan University
    May 23, 2022

    Locally Advanced Cervical Cancer Trial in Villejuif (Atezolizumab, Radiotherapy, Cisplatin)

    Recruiting
    • Locally Advanced Cervical Cancer
    • Villejuif, Val De Marne, France
      Gustave Roussy
    Feb 15, 2022

    Recurrent/Metastatic Gastric Cancer Trial in Seoul (Nivolumab, Paclitaxel)

    Completed
    • Recurrent/Metastatic Gastric Cancer
    • Nivolumab, Paclitaxel
    • Seoul, Korea, Republic of
      Yonsei University Health System, Severance Hospital
    Sep 9, 2022

    Fruquintinib Plus PD-1 in Refractory MSS Metastatic Colorectal

    Completed
    • Colorectal Cancer
    • Fruquintinib combined with anti-PD-1 antibodies
    • ChangSha, Hunan, China
      Hunan Cancer Hospital
    Aug 27, 2023

    Anti-Programmed Cell Death Protein 1 Immunotherapy in Head and

    Recruiting
    • Head and Neck Cancer
    • Strasbourg, France
      Institut de cancérologie Strasbourg Europe
    Apr 14, 2022

    Liver Diseases, Hepatocellular Carcinoma, Immunotherapy Trial in Guangzhou (bTAE-HAIC, Lenvatinib, Sintilimab)

    Not yet recruiting
    • Liver Diseases
    • +4 more
    • bTAE-HAIC
    • +2 more
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    Sep 30, 2023

    Liver Diseases, Hepatocellular Carcinoma, Immunotherapy Trial in Guanzhou (bTAE-HAIC, Lenvatinib, Camrelizumab)

    Not yet recruiting
    • Liver Diseases
    • +4 more
    • bTAE-HAIC
    • +2 more
    • Guanzhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    Sep 24, 2023

    Malignant Melanoma Trial (tremelimumab/durvalumab, ipilimumab/nivolumab and nivolumab monotherapy)

    Withdrawn
    • Malignant Melanoma
    • tremelimumab/durvalumab, ipilimumab/nivolumab and nivolumab monotherapy
    • (no location specified)
    Nov 12, 2021

    Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor, Radiotherapy Trial in Guangzhou (Toripalimab,

    Not yet recruiting
    • Muscle-Invasive Bladder Carcinoma
    • +2 more
    • Guangzhou, Guangdong, China
      Cancer Center, Sun Yat-sen University
    Aug 3, 2023

    Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite

    Completed
    • Metastatic Colorectal Adenocarcinoma
    • regorafenib plus anti-PD-1 antibodies
    • Changsha, Hunan, China
      Hunan Cancer hospital
    Jul 4, 2023

    NSCLC Trial (pembrolizumab, carboplatin, paclitaxel)

    Active, not recruiting
    Has Results
    • Non-small Cell Lung Cancer
    • pembrolizumab
    • +3 more
    • (no location specified)
    Aug 18, 2022

    Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Chapel Hill (Nivolumab, Pembrolizumab)

    Recruiting
    • Relapsed Hodgkin Lymphoma
    • Refractory Hodgkin Lymphoma
    • Nivolumab
    • Pembrolizumab
    • Chapel Hill, North Carolina
      Lineberger Comprehensive Cancer Center at University of North Ca
    Jul 22, 2022

    Locally Advanced Basal Cell Carcinoma Trial in Philadelphia (biological, procedure, other)

    Not yet recruiting
    • Locally Advanced Basal Cell Carcinoma
    • Cemiplimab
    • +3 more
    • Philadelphia, Pennsylvania
      Thomas Jefferson University Hospital
    Jun 28, 2023

    NSCLC Trial (pembrolizumab, carboplatin, paclitaxel)

    Active, not recruiting
    Has Results
    • Non-small Cell Lung Cancer
    • pembrolizumab
    • +3 more
    • (no location specified)
    Aug 18, 2022

    Acute Lymphoblastic Leukemia in Pediatric Trial in Sohag (flow cytometric immunophynotyping)

    Not yet recruiting
    • Acute Lymphoblastic Leukemia in Pediatric
    • flow cytometric immunophynotyping
    • Sohag, Egypt
      Sohag University Hospital
    Jun 19, 2022

    NSCLC Trial in Marietta, Taichung City, Tainan (Sacituzumab Govitecan, Pembrolizumab)

    Recruiting
    • Carcinoma, Non-Small-Cell Lung
    • Sacituzumab Govitecan
    • Pembrolizumab
    • Marietta, Georgia
    • +2 more
    Jan 27, 2023

    Hodgkin's Lymphoma Trial in Seattle (Pembrolizumab, Umbralisib)

    Terminated
    • Hodgkin's Lymphoma
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Jul 22, 2022